Drugs / hTERT
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01660529 | Jun 2012 → Nov 2015 | breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02960594 | Dec 2014 → Nov 2018 | breast cancer, colorectal cancer, esophageal cancer, gastric cancer +5 | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hTERT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01660529 ↗ |
| Known as | INO-1400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02960594 ↗ |
| Modality | Vaccine | “hTERT/survivin/CMV multipeptide vaccine” NCT01660529 ↗ |
| Route | Subcutaneous | “subcutaneous vaccinations” NCT01660529 ↗ |